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While prostate and breast cancers are both highly prevalent and treatable using hormone suppression therapy, a constellation of
side eﬀects ensue, which mimic typical aging eﬀects but at an accelerated pace. Because strength training is considered to be an
intervention of choice for addressing the musculoskeletal and metabolic consequences of normal aging in older adults, it may
be an eﬀective intervention to attenuate or reverse the side eﬀects of hormone-dependent cancer treatment. This paper provides
an overview of the independent eﬀects of strength training on common musculoskeletal and metabolic side eﬀects of hormone-
dependent therapy used for prostate and breast cancers. Strength training appears to be an eﬀective complementary therapy for
some of the adverse eﬀects of prostate and breast treatment. Future research needs to address potential mechanisms to explain
recent ﬁndings and to explore the role of strength training in addressing speciﬁc risk factors resulting from cancer treatment.
1.Introduction
Cancer is the leading cause of death worldwide, accounting
for 7.4 million deaths (∼13% of all fatalities) in 2004 and is
projected to rise to more than 12 million deaths by the year
2030 [1]. Prostate cancer (PCa) in men (28% of all cancer
sites) and breast cancer (BCa) in women (28%) are the most
prevalent types of cancer in the US [2]. They are the second
leading causes of cancer-related deaths for men and women
in the US, respectively [2], while BCa is the leading cause of
cancer death in women across the globe [1].
The prevalence of all cancers increases with age [2],
with those ≥65 years of age accounting for >60% of all
cancers [3]. Because this age group is also more likely
to have other comorbid conditions, such as osteoporosis,
arthritis, and cardiovascular disease than youngeragegroups
[3], treatment options become more complicated.Moreover,
these patients tend to avoid physical activity, leading to
some of the same adverse consequences as those previously
experienced by cardiac patients who failed to engage in
physical activity [4]. As is the case for cardiac patients, this
course of action can result in losses of functional capacity
and quality of life (QoL) measures for cancer patients. In
contrast, regular exercise can reduce cancer-related fatigue
and other adverse symptoms of the disease, as well as
substantially improve the QoL in cancer patients [4, 5].
Because ﬁve-year survival rates in localized PCa and BCa
remain high [2], QoL related issues are of great concern.
Although regular exercise has long been recommended for
cancer patients, investigators have only recently focused on
some of the speciﬁc musculoskeletal and metabolic adverse
consequences (side eﬀects) of cancer treatment, particularly
those of hormone ablation medications.
There appears to be an interesting parallel between the
many side eﬀects of both PCa and BCa treatment and
the changes that occur with typical aging [6–9], but at
an accelerated pace. Given the role of strength training
(ST) as a countermeasure for the age-related changes in
body composition and physical function [10], this review
will focus on the eﬀects of ST on the side eﬀects elicited
from medications used in the two most common hormone-
dependent cancers, that is, PCa and BCa. It will not include
combined exercise training programs (e.g., those using both
aerobic and resistance exercise) unless combined training2 Journal of Aging Research
programs are the only source of information available on the
side eﬀect being discussed.
2.TreatmentsforPCaand BCa
Thereisawidevarietyoftreatment optionsforbothPCaand
BCa,dependingonapatient’smedicalhistory,diagnosis, age,
and current state of health. Although primary treatment for
P C am a yi n c l u d er a d i c a lp r o s t a t e c t o m y ,r a d i a t i o n ,a n do t h e r
therapies, a common adjuvant treatment is the suppression
of endogenous testosterone through the use of hormonal
agents [11]. Likewise, while surgery is the primary therapy
for BCa treatment, hormone suppression therapy serves as
an important adjuvant therapy [12]. Chemotherapy is also
used as a systemic treatment for BCa, either before surgery
(neoadjuvant) or after (adjuvant) as needed. However, a
common consequence of chemotherapy is ovarian failure
[13, 14] and the onset of premature menopause.
Because most PCas are androgen dependent, androgen
deprivation therapy (ADT) is a commonly used treatment
for PCa [11] and results in what is sometimes referred
to as a chemical castration. Although this treatment slows
the growth of existing tumors, thereby potentially saving
lives, the associated suppression of testosterone also leads to
n u m e r o u sa d v e r s es i d ee ﬀects, including an increase in the
number of comorbidities, which ultimately have a negative
impact on QoL.
Analogous to the treatment of PCa, hormonal therapy
for the treatment of BCa is to inhibit the eﬀects of
estrogen. This can be accomplished using selective estrogen-
receptor modulators, such as tamoxifen [15], or aromatase
inhibitors, another example of an antiestrogen treatment
[12]. Both treatments reduce growth in estrogen-responsive
tumors. Historically, tamoxifen has been a mainstay in BCa
treatment and can be administered to both premenopausal
and postmenopausal women [15] while aromatase inhibitors
are typically reserved for postmenopausal women [12].
3.SideEffectsofPCaand BCa Therapyand
StrengthTraining
3.1. Does Hormone Therapy Mimic Aging Eﬀects?
Sex hormone levels decline gradually with age in men and,
abruptly, with menopause in women. Previously, the cessa-
tion of endogenous production of androgens and estrogens
during PCa and BCa treatment has been equated with
increases in hormone-dependent age-related changes [6, 9].
While it is evident that treatment of hormone-dependent
cancers via ablation or modulation of the sex hormones
is eﬀective in shrinking tumor masses and extending long-
termsurvival rates, suchtreatments also bringabout declines
in muscle mass [16–20], strength [21, 22], and bone
mineral density (BMD) [17, 22–27]a n di n c r e a s e si nf a t
mass [16, 17, 19–21, 28, 29], insulin resistance [30–33],
and fatigue [17, 34–36]. Collectively, these eﬀects nega-
tively inﬂuence physical function [18, 22, 37–39]a n dQ o L
[21, 34, 36, 40, 41].
ST has been advocated as the intervention of choice for
addressing many age-related declines [7, 8]. In this regard,
many researchers have demonstrated that ST can reverse
age-associated losses in muscle mass [42, 43], strength [44],
muscle power [42, 45], bone loss [46], insulin sensitivity
[47, 48], and increases in regional fat deposition [49], as well
as the deterioration of muscle functional abilities, leading
to declines in activities of daily living [50, 51]. Losses in
muscle mass are also associated with declines in resting
metabolic rate, which can lead to obesity. In this context, our
group has shown increases in resting metabolic rate with ST
[52, 53]. These results from healthy individuals support the
hypothesis that ST can reverse or delay the musculoskeletal
and metabolic consequences of hormone-dependent cancer
treatment. Below is an overview of the evidence from studies
that have tested this hypothesis.
3.2. Muscle Mass and Strength. Signiﬁcant loss of muscle
mass is observed within the ﬁrst year of ADT in PCa patients
[16, 17, 19, 20], and the longer the treatment period, the
greater the loss in muscle mass [18]. When compared with
healthycontrolsandPCapatientsnotundergoingADT,ADT
treatment revealed substantial reductions in muscle mass as
well as strength [21, 22]. Ultimately, the loss of muscle mass
and strength may be adversely linked to survival because
higher levels of muscular strength are associated with lower
cancer mortality risk in men, independent of other risk
factors [54]. Declines in strength and mass may also occur
in BCa patients during treatment, but the cause of this eﬀect
is unclear. In one study involving BCa patients undergoing
localized treatment alone versus localized treatment and
chemotherapy, there was a slight decline (<0.5kg) in fat-free
mass over 12 months in the dual treatment group while the
localized treatment only group increased fat-free mass [28].
However, this diﬀerence was no longer present when results
were adjusted for other factors that may have inﬂuenced fat-
free mass, such as age, race, radiation therapy, baseline body
mass index, and baseline fat-free mass. In another study,
the eﬀects of chemotherapy and tamoxifen on fat-free mass
depended on what method was used to assess fat-free mass
[55]. Other investigators have also observed no treatment
eﬀect on fat-free mass [56, 57]o rs t r e n g t h[ 58]i nB C a
patients. Thus, declines in muscle mass and strength appear
to be a concern primarily for PCa patients on ADT, given the
anabolic role of androgens on muscle mass [59].
In two separate randomized trials, Segal et al. [60, 61]
observed strength gains with ST in patients with PCa under-
goingADT.AnotherstudyshowedthatSTimprovedstrength
but without changes in whole body fat-free mass in PCa
patients on ADT, though a signiﬁcant increase in quadriceps
thickness was reported [62]. Hansen et al. [63]e x a m i n e d
the muscle hypertrophic response in PCa patients with and
without ADT. Using eccentric resistance exercise, the men
not on ADT experienced signiﬁcant regional hypertrophy
whereas the men on ADT did not. No signiﬁcant diﬀerences
between groups were observed, but the low statistical power
from the small sample size may have contributed to this
result. In contrast, we recently detected signiﬁcant increasesJournal of Aging Research 3
in thigh muscle volume, directly assessed by computed
tomographyandwhole bodyfat-free mass withSTinAfrican
Americans with PCa on long-term ADT (Hanson et al.,
unpublished data). BCa patients undergoing treatment are
also able to increase their strength levels with ST [41, 57,
58, 64]. However, many of the existing exercise and cancer
studies use a mixture of aerobic and ST protocols, which
precludes the independent eﬀects of ST. Nevertheless, it is
likely that the strength increases reported in these studies
are due to ST, given that aerobic exercise training does not
typically result in signiﬁcant strength increases.
3.3. Muscle Power. Muscle power is the product of the force
and speed of muscular contractions. It is a strong predictor
oftheabilitytoperformtheactivitiesofdailylivingnecessary
for maintaining a high QoL in older adults [65], to an even
greater extent than muscle strength [66, 67]. For this reason,
power has the potential to be an important QoL indicator
for patients with cancer. While muscle power declines with
advancing age [68], the eﬀects of cancer therapy on muscle
power have not yet been reported in PCa or BCa patients.
The authors [42]a n do t h e r s[ 45, 69]h a v er e p o r t e d
signiﬁcant improvements in peak muscle power with ST
in older healthy adults. Since movement speed is unlikely
to improve with hormone therapy or decline with ST, it
is likely that ST would improve power in cancer patients
on hormone therapy, as it does for healthy people, given
the reported ST-induced strength increases in these patients.
To the best of our knowledge, this has not been studied.
However, similar to our unpublished muscle volume data,
we observed signiﬁcant improvements in muscle power at
various relative loads with ST (Hanson et al., unpublished
data).
3.4. Bone Mineral Density. The hormone therapies used for
PCa [17, 22, 27]a n dB C a[ 15, 58, 70, 71] are both associated
w i t hal o s si nB M D .H o w e v e r ,t h es p e c i ﬁ ct y p eo fB C a
treatment aﬀects BMD diﬀerently, as patients on aromatase
inhibitors led to declines in BMD while those on tamoxifen
experienced signiﬁcant increases [23–25]. Moreover, bone
lossassociated with aromatase inhibitortreatment in women
with BCais twofold higher than that of healthy, age-matched
postmenopausal women [26]. Chemotherapy treatment for
BCaalsoreducesBMD,probablyasaresultofovarianfailure,
and occurs in ∼71% of patients [13, 14, 58]. Patients who
retained ovarian function did not show any loss in BMD
[14]. With the possible exception of fatigue, BMD loss and
fracture risk appear to be the single largest consequence of
BCa treatment.
We could ﬁnd only one study each for PCa and BCa
reporting the eﬀects of ST on bone mass [58, 62]. ST for
20 weeks did not result in any changes in BMD in PCa
patients [62]. In a randomized clinical trial of BCa patients,
six months of home-based aerobic training versus resistance
training versus usual care, demonstrated BMD declines of
−0.76%, −4.92%, and −6.23%, respectively, with only a
signiﬁcant diﬀerence between the aerobic training and usual
care groups [58]. However, the ST program was performed
using Thera-Bands and light resistance. Recently, Newton
et al. [72] proposed a study that could potentially be the best
controlled and most thorough physiological investigation on
ST eﬀects in patients on ADT. In particular, they propose to
address the impact of ST on bone density as an indicator of
f r a c t u r er i s k .T h e yw i l la l s od e t e r m i n et h ee ﬀects of impact-
loading exercise on bone mass. The rationale for this latter
aspect of their study is that high and frequent impact forces
on long bones are thought to stimulate bone formation.
Despitethelackofdirectevidenceofsigniﬁcant improve-
ments in BMD in cancer patients, ST can increase BMD in
healthy older adults [46, 73–75]. Although not all studies
report improvements, those that have compared ST results
to controls support the hypothesis that ST is eﬀective for
preventing or delaying the loss of BMD over time in older
adults. Therefore, it is logical that a similar eﬀect could be
present in cancer patients if suﬃcient intensities are used,
despitelimitedevidencetothecontrary [58].Whileincreases
in BMD directly reduce fracture risk, it has been argued that
the ST-induced gains (<5%) are not suﬃcient to overcome
the estimated 20% gain in BMD that may be necessary to
actually prevent a fracture during falls [76]. Instead, ST
m a yi n d i r e c t l yr e d u c ef r a c t u r er i s kb yi m p r o v i n gw a l k i n g
mechanics, balance, and strength, some of which have been
observed in PCa patients during treatment [62], leading to a
reduced risk of falling.
3.5. Fat Mass. Unlike fat-free mass, treatment of both PCa
[16–20,61,77]andBCa[28,29,55] isconsistentlyassociated
with a signiﬁcant increase in fat deposition. The increase
in fat mass can lead to obesity, diabetes, and metabolic
syndrome. Although not directly assessed in previous cancer
studies, it is quite likely that PCa and BCa therapies increase
fat inﬁltration in muscle, leading to the accumulation of
intermuscular fat [78]. This too has important health impli-
cationsbecauseelevatedlevelsofintermuscularfat havebeen
linked to insulin resistance and to the development of type 2
diabetes [79]. In addition, fat inﬁltration is associated with
reduced strength [80], poorer leg function [81], and greater
incidence of mobility limitations in older adults [82]. While
weight gain is widely reported with BCa treatment, it is not
well established if the gain is speciﬁcally due to tamoxifen. In
a cohort of women who experienced weight gain of 1.7kg
and increased body fat 2.1%, there were no diﬀerences in
weight and percent body fat increases between those being
treated with tamoxifen and those who were not [29].
Segal et al. [61] found that ST may play a preventative
role against the increase in body fat associated with PCa
treatment. The patients who performed ST had no change
in fat mass while those in the control group experienced
signiﬁcant increases in fat mass. Along these same lines,
Galv˜ ao et al. [62] reported no change in body fat with ST
and ADT, but had no control group for comparison. Similar
ﬁndings of no signiﬁcant reductions in body fat have been
reported in BCa [57]. Mixed training protocols (ST and
aerobic exercise training) can result in a signiﬁcant loss of
fat mass in some [56]b u tn o ta l l[ 83] studies in BCa patients
during treatment.4 Journal of Aging Research
3.6.Insulin Resistance. Insulinresistancereferstoareduction
in the eﬀectiveness of glucose uptake. This defect is linked
to a whole spectrum of disorders, including obesity, cardio-
vascular disease, and the metabolic syndrome. Basaria et al.
[30] observed a substantially higher prevalence of insulin
resistance in PCa patients on ADT than in two other control
groups, one in normal healthy controls and the other in a
group having a similar disease state, but not on ADT. These
results were independent of age and obesity. Similar declines
in insulin sensitivity were found after a 12-week prospective
study at the onset of ADT[32].Inaddition, twoindependent
reviews have corroborated this conclusion showing a strong
link between ADT administration and insulin resistance [77,
84] and that this association becomes evidentwithin the ﬁrst
few months of treatment. The authors emphasize the need
for men receiving ADT to develop healthy lifestyle practices,
such as regular exercise, particularly ST [84]. Furthermore,
Basaria [77] found that ADT use for 12 months revealed
a higher prevalence of diabetes, metabolic syndrome, and
death from cardiovascular disease compared to controls.
Similar to PCa patients, BCa patients on hormone therapy
also have elevated insulin, glucose, and HbA1c levels [33].
Moreover, low doses of hormone therapy result in a loss of
insulin sensitivity in women at a high risk for BCa [31].
Women being treated for BCa also had higher C-reactive
protein levels and incidence rates of metabolic syndrome
[33, 85].
To the best of our knowledge, however, the indepen-
dent eﬀect of ST has not been studied in cancer patients
undergoing treatment for hormone-dependent cancers. The
best evidence available is that BCa patients who underwent
supervised ST and home-based aerobic exercise had signif-
icant decreases in fasting insulin levels with no change in
the control group [83]. There was only a trend for between-
group diﬀerences and no change in fasting glucose levels
were found. Patients on ADT undergoing a mixed training
protocol had no adjusted group diﬀerences after 12 weeks of
training for insulin or glucose [86]. In healthy individuals,
ST reduces insulin resistance and is as eﬀective as aerobic
training in both healthy older adults [48]a n dd i a b e t i c s
[47]. ST improves the insulin responses during oral glucose
tolerance testing and hyperinsulinemic-euglycemic clamps
in older men [87, 88] and postmenopausal women [89].
The similarity of ﬁndings between ST eﬀects in healthy
older adults and those undergoing cancer treatments for
other risk factors supports the hypothesis that ST would
also produce improvements in insulin resistance in can-
cer survivors. The data available do not entirely support
this, but the independent eﬀects of ST have yet to be
evaluated.
3.7. Fatigue and Physical Activity Levels. Fatigue may be the
most prevalent and distressing side eﬀect during and after
cancer treatment [4, 5], as high numbers of patients report
suﬀering from chronic fatigue during this time [17, 34–
36, 55, 90]. It is likely that both aging and hormone therapy
contributetofatiguebyelicitingphysiologicalevents(suchas
anemia, declines in strength and fat-free mass, and increased
fat mass) that promote loss in fatigue resistance and the
ability or willingness to engage in physical activity. Both
PCa and BCa patients have reduced physical activity levels
after the onset of treatment [17, 91]. Lower levels of physical
activity, in part, result in overall reductions in ﬁtness levels,
leading to declinesin physical function and ultimately to loss
in QoL.
Compliance to regular exercise may break the vicious
cycle of fatigue followed by avoidance of physical activity
[4, 5]. Segal et al. [60, 61] found that fatigue negatively
impacts on activities of daily living and QoL measures but
both were improved as a result of ST in men with PCa. They
also observed improvements in muscle endurance with the
ST group compared to a control group [60]. This ﬁnding has
been corroborated by others [62], supporting the hypothesis
that ST improves fatigue resistance in patients undergoing
ADT. Reductions in fatigue with ST have also been observed
in patients being treated for BCa [57], but these reductions
were notsigniﬁcantlydiﬀerentfromthoseofacontrolgroup.
As described for other factors previously, the independent
eﬀects of ST are not entirely clear because many studies
used both aerobic and ST [36, 92, 93]. There is little doubt,
however, that regular exercise reducesfatigue inBCapatients
undergoing therapy.
3.8. Physical Function. The loss of physical function during
ADT treatment is a common side eﬀect [18, 22, 37]a n d
is likely the result of decreased muscle mass and physical
activity levels coupled with increases in fat mass and fatigue.
Investigators who study functional abilities in men with PCa
often administer a standardized battery of tests that simulate
activities of daily living. This form of testing is seldom
reported in women with BCa, rather the declines in function
often focus on shoulder dysfunction and lymphedema
following surgery rather than hormone treatments [39]o r
assess functionviaquestionnaire.Reducedshoulderfunction
in BCa is associated with poorer physical condition, minimal
physical activity, increased body mass index, and poorer
physical QoL [38], similar to the loss of function and QoL
associated with PCa.
ST in men on ADT led to reported improvements of 7
to 27% in simulated activities of daily living [62]. Others
have also reported improved activities of daily living in
men with PCa but have used either combined exercise
programs or resistance in which only the lengthening phase
of the exercise is loaded (eccentric) [63, 86]. Studies on the
eﬀects of ST on upper body function are limited in BCa
patients, possibly because ST was previously contraindicated
due to concerns of lymphedema. However, recent studies
have speciﬁcally addressed this concern. While no data are
available on physical function, adverse events and worsening
oflymphedemasymptomsdidnotoccurwithST[57,64,94].
The fact that women with BCa can safely participate in this
type of exercise without adverse consequences provides a
rationale for future studies to examine the role of ST on
upper body function given the connection between limited
function and QoL [38].Journal of Aging Research 5
3.9. Quality of Life. Quality of life is arguably the most
egregious side eﬀect resulting from cancer treatment and
is intertwined with strength, body composition, fatigue,
and physical function. The changes observed with cancer
treatment to the above traits are likely to inﬂuence QoL.
Thus, it is not surprising that men and women undergoing
hormone therapy for PCa and BCa report reduced QoL
indicators [21, 34, 36, 40, 41]. The questionnaires used to
assess QoL varied between studies, although several trends
appear to be evident. For example, lower QoL scores were
observed for the physical function but not the mental health
in both PCa and BCa patients [21, 40, 41]. Other studies
that used QoL questionnaires speciﬁc to each cancer type
demonstrated reducedoverallscoreswith treatment [34,36].
Improved QoL scores with ST are observed in some studies
in PCa and BCa patient populations [41, 60, 61], though
not in others [57, 63]. Moreover, Ohira et al. [41]r e p o r t e d
that several musculoskeletal improvements with ST were
correlated with higher QoL indicators.
4.Conclusionsand FutureDirections
Some of the eﬀects of hormone-related treatments for
persons with PCa and BCa are similar to the typical eﬀectsof
normal aging but occurat an accelerated pace. These include
a long list of musculoskeletal, metabolic, body composition,
and functional outcomes. ST appears to have a positive
inﬂuence on many, but not all of these characteristics. In
particular, ST is eﬀective in reversing the loss of strength
and function and may be able to slow fat gains and bone
losses common to both types of cancer treatments. Due
to the widespread use of mixed training protocols, there
a r es o m es i d ee ﬀects that are reduced from training, but
the independent eﬀects of ST cannot be distinguished from
eﬀects of other training modalities, such as aerobic exercise.
With ﬁve-year survival rates for BCa and PCa approaching
100% [2], maintaining high QoL in cancer patients is of
paramount importance. In this regard, ST may contribute
toward achieving this goal by serving as an eﬀective adjunct
therapyandcountermeasuretotheadverseeﬀectsofPCaand
BCa treatment.
Over the past decade, the role of exercise has expanded
from a means of improving QoL in cancer patients toward
addressing speciﬁc risk factors resulting from cancer treat-
ment, as well other lifestyle choices that limit function and
inﬂuence QoL. Future research should address the issue of
whether ST can (1) reverse ADT-induced muscle atrophy
through direct assessments of muscle area in PCa patients,
(2) enhance direct measures of whole body physical function
inBCapatients,(3)improvemusclepowerand bonemineral
densitiesinbothpopulations,and(4)establisharelationship
between favorable functional outcomes (activities of daily
living, fatigue, QoL) and speciﬁc ST-induced adaptations
(strength, power, body composition). This additional infor-
mation will help guide clinicians in exercise prescription
designed speciﬁcally to reduce comorbidities and particular
side eﬀects to enhance QoL in men and women undergoing
hormone treatment for PCa and BCa, respectively.
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